Fazio Victor W, Cohen Zane, Fleshman James W, van Goor Harry, Bauer Joel J, Wolff Bruce G, Corman Marvin, Beart Robert W, Wexner Steven D, Becker James M, Monson John R T, Kaufman Howard S, Beck David E, Bailey H Randolph, Ludwig Kirk A, Stamos Michael J, Darzi Ara, Bleday Ronald, Dorazio Richard, Madoff Robert D, Smith Lee E, Gearhart Susan, Lillemoe Keith, Göhl Jonas
Cleveland Clinic, Cleveland, Ohio, USA.
Dis Colon Rectum. 2006 Jan;49(1):1-11. doi: 10.1007/s10350-005-0268-5.
Although Seprafilm has been demonstrated to reduce adhesion formation, it is not known whether its usage would translate into a reduction in adhesive small-bowel obstruction.
This was a prospective, randomized, multicenter, multinational, single-blind, controlled study. This report focuses on those patients who underwent intestinal resection (n = 1,701). Before closure of the abdomen, patients were randomized to receive Seprafilm or no treatment. Seprafilm was applied to adhesiogenic tissues throughout the abdomen. The incidence and type of bowel obstruction was compared between the two groups. Time to first adhesive small-bowel obstruction was compared during the course of the study by using survival analysis methods. The mean follow-up time for the occurrence of adhesive small-bowel obstruction was 3.5 years.
There was no difference between the treatment and control group in overall rate of bowel obstruction. The incidence of adhesive small-bowel obstruction requiring reoperation was significantly lower for Seprafilm patients compared with no-treatment patients: 1.8 vs. 3.4 percent (P < 0.05). This finding represents an absolute reduction in adhesive small-bowel obstruction requiring reoperation of 1.6 percent and a relative reduction of 47 percent. In addition, a stepwise multivariate analysis indicated that the use of Seprafilm was the only predictive factor for reducing adhesive small-bowel obstruction requiring reoperation. In both groups, 50 percent of first adhesive small-bowel obstruction episodes occurred within 6 months after the initial surgery with nearly 30 percent occurring within the first 30 days. Additionally no first adhesive small-bowel obstruction events were reported in Years 4 and 5 of follow-up.
The overall bowel obstruction rate was unchanged; however, adhesive small-bowel obstruction requiring reoperation was significantly reduced by the use of Seprafilm, which was the only factor that predicted this outcome.
尽管已证明Seprafilm可减少粘连形成,但尚不清楚其使用是否会转化为粘连性小肠梗阻的减少。
这是一项前瞻性、随机、多中心、跨国、单盲对照研究。本报告聚焦于接受肠切除术的患者(n = 1701)。在关闭腹腔前,患者被随机分为接受Seprafilm治疗组或不治疗组。Seprafilm应用于整个腹腔的易形成粘连的组织。比较两组肠梗阻的发生率和类型。在研究过程中,采用生存分析方法比较首次发生粘连性小肠梗阻的时间。粘连性小肠梗阻发生的平均随访时间为3.5年。
治疗组和对照组在总体肠梗阻发生率上无差异。与未治疗患者相比,Seprafilm治疗的患者需要再次手术的粘连性小肠梗阻发生率显著更低:1.8%对3.4%(P < 0.05)。这一发现表明需要再次手术的粘连性小肠梗阻绝对减少了1.6%,相对减少了47%。此外,逐步多变量分析表明,使用Seprafilm是减少需要再次手术的粘连性小肠梗阻的唯一预测因素。在两组中,50%的首次粘连性小肠梗阻发作发生在初次手术后6个月内,近30%发生在头30天内。此外,在随访的第4年和第5年未报告首次粘连性小肠梗阻事件。
总体肠梗阻发生率未变;然而,使用Seprafilm可显著降低需要再次手术的粘连性小肠梗阻,这是预测这一结果的唯一因素。